V
Vijay Kumar Prajapati
Researcher at Central University of Rajasthan
Publications - 117
Citations - 3698
Vijay Kumar Prajapati is an academic researcher from Central University of Rajasthan. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 31, co-authored 93 publications receiving 2754 citations. Previous affiliations of Vijay Kumar Prajapati include Institute of Medical Sciences, Banaras Hindu University & Banaras Hindu University.
Papers
More filters
Journal ArticleDOI
Efficacy of Miltefosine in the Treatment of Visceral Leishmaniasis in India After a Decade of Use
Shyam Sundar,Anup Singh,Madhukar Rai,Vijay Kumar Prajapati,Avinash Singh,Bart Ostyn,Marleen Boelaert,Jean-Claude Dujardin,Jaya Chakravarty +8 more
TL;DR: There is a substantial increase in the failure rate of oral miltefosine for treatment of VL in India as compared to the phase III trial that led to registration of the drug a decade ago.
Journal ArticleDOI
Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach.
TL;DR: This study warrants the experimental validation to ensure the immunogenicity and safety profile of presented vaccine construct which may be further helpful to control VL infection.
Journal ArticleDOI
Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection.
Mudassar Ali,Rajan Kumar Pandey,Nazia Khatoon,Aruna Narula,Amit Mishra,Vijay Kumar Prajapati +5 more
TL;DR: This work used immunoinformatics approaches to develop a multi-epitope based subunit vaccine for dengue which can generate various immune responses inside the host and confirmed the humoral and cell mediated immune response developed by designed vaccine.
Journal ArticleDOI
Novel Immunoinformatics Approaches to Design Multi-epitope Subunit Vaccine for Malaria by Investigating Anopheles Salivary Protein
TL;DR: The designed subunit vaccine was found to induce anti-salivary immunity which may have the ability to prevent the entry of Plasmodium sporozoites into the human host.
Journal ArticleDOI
Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes.
Vijay Kumar Prajapati,Kalpana Awasthi,Shalini Gautam,Thakur Prasad Yadav,Madhukar Rai,O.N. Srivastava,Shyam Sundar +6 more
TL;DR: The results of these experiments clearly demonstrate that f-CNT-AmB has significantly greater antileishmanial efficacy than AmB and had no significant cytotoxic effects.